# Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis

> **NCT06718933** · PHASE1,PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 74 (estimated)

## Conditions studied

- Breast Cancer Metastatic
- Breast Cancer Brain Metastases

## Interventions

- **DRUG:** SHR-A1811
- **DRUG:** Bevacizumab
- **DRUG:** Pyrotinib

## Key facts

- **NCT ID:** NCT06718933
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-08
- **Primary completion:** 2026-08-31
- **Final completion:** 2027-02-28
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2025-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06718933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06718933, "Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06718933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*